G01N 2333/70535
Fc-receptors
Official title: Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
G01N2333/70535 (Fc-receptors) appears on 109 US grants and 210 published applications in this corpus.
Search patents in G01N- Granted patents
- 109
- Published applications
- 210
- Assignees
- 114
- Inventors
- 444
- Latest grant
- 4 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1999 | 1 | 0 |
| 2000 | 1 | 0 |
| 2001 | 1 | 0 |
| 2002 | 0 | 2 |
| 2003 | 1 | 7 |
| 2004 | 2 | 2 |
| 2005 | 0 | 6 |
| 2006 | 2 | 4 |
| 2007 | 5 | 6 |
| 2008 | 3 | 4 |
| 2009 | 1 | 4 |
| 2010 | 3 | 5 |
| 2011 | 1 | 6 |
| 2012 | 5 | 1 |
| 2013 | 1 | 4 |
| 2014 | 3 | 8 |
| 2015 | 7 | 19 |
| 2016 | 2 | 17 |
| 2017 | 6 | 11 |
| 2018 | 13 | 10 |
| 2019 | 8 | 14 |
| 2020 | 8 | 12 |
| 2021 | 5 | 15 |
| 2022 | 3 | 6 |
| 2023 | 5 | 11 |
| 2024 | 7 | 9 |
| 2025 | 8 | 21 |
| 2026 | 7 | 6 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Antibody blocking human FcγRIIIA and FcγRIIIB4 Aug 2026US 12,698,331 B2Centre National de la Recherche Scientifique (CNRS)
- Compositions and methods for NK-92 cells expressing native CD1614 Jul 2026US 12,681,020 B2ImmunityBio, Inc.
- Method for detection of CD16b23 Jun 2026US 12,663,422 B252 North Health Ltd
- Anti-CD32A antibodies and their use for evaluating the presence of a viral reservoir16 Jun 2026US 12,656,335 B2Centre National De La Recherche Scientifique
- Biodosimetry panels and methods16 Jun 2026US 12,658,304 B2Meso Scale Technologies, LLC.
- Humoral Immune Activators for the Treatment of Humoral Immunosuppressed Pathologies, Cancer and Infectious Disease and Humoral Immune Suppressors for the Treatment of Inflammatory Diseases3 Sep 2026US 2026/0256811 A1Navrogen, Inc.
- Method and treatment9 Jul 2026US 2026/0194526 A1
- Novel target for anti-cancer and immune-enhancing2 Jul 2026US 2026/0184774 A1Genome and Company
- Control cell populations for detection of paroxysmal nocturnal hemoglobinuria14 May 2026US 2026/0133112 A1Biolegend, Inc.
- Compositions and methods for treating inflammatory diseases14 May 2026US 2026/0133193 A1University of Washington
Most cited
By later US patents
- Identification and engineering of antibodies with variant Fc regions and methods of using same227US 7,355,008 B2MacroGenics, Inc. · 2008
- Identification and engineering of antibodies with variant Fc regions and methods of using same71US 8,003,774 B2MacroGenics, Inc. · 2011
- Identification and engineering of antibodies with variant Fc regions and methods of using same64US 8,192,737 B2MacroGenics, Inc. · 2012
- Human monoclonal antibodies to FC alpha receptor (CD89)40US 7,192,582 B2Medarex, Inc. · 2007
- Cyanidin compositions and therapeutic and diagnostic uses therefor35US 6,146,837 AMedarex, Inc. · 2000